2024/08/14 16:31:09 | |
---|---|
Price | |
1,155.6492 USD | |
Difference | 7.16% (77.18) |
ISIN | US75886F1075 |
Symbol | REGN |
Exchange | London Stock Exchange |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 116,130 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 1,155.6492 USD |
High | 1,155.6492 USD |
Low | 1,155.6492 USD |
Close (prev. day) | 1,078.4689 USD |
VWAP | 1,155.64922 USD |
Volume (pcs) | 476 |
Trading volume | 548,933.38 |
Number of trades | 2 |
Last size | 475 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings | ||
2024/07/03 | Global Strategy 3Q 2024 | ||
2024/06/21 | Global Equity Ratings |
2024/08/14 16:31:09 | |
---|---|
Price | |
1,155.6492 USD | |
Difference | 7.16% (77.18) |
ISIN | US75886F1075 |
Symbol | REGN |
Exchange | London Stock Exchange |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 116,130 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 1,155.6492 USD |
High | 1,155.6492 USD |
Low | 1,155.6492 USD |
Close (prev. day) | 1,078.4689 USD |
VWAP | 1,155.64922 USD |
Volume (pcs) | 476 |
Trading volume | 548,933.38 |
Number of trades | 2 |
Last size | 475 |
6m | 1Y | 3Y | |
Perf (%) | - | - | - |
Perf (abs.) | - | - | - |
Beta | 0.59 | 0.58 | 0.57 |
Volatility | 2.72 | 6.44 | 6.36 |
Ø price 5 days | Ø volume 5 days (pcs.) | 1,155.6492 USD (106) |
Ø price 30 days | Ø volume 30 days (pcs.) | 1,087.8696 USD (90) |
Ø price 100 days | Ø volume 100 days (pcs.) | 1,026.7107 USD (171) |
Ø price 250 days | Ø volume 250 days (pcs.) | 946.1753 USD (286) |
YTD High | date | 1,155.6492 USD (2024/08/14) |
YTD Low | date | 895.3700 USD (2024/01/09) |
52 Weeks High | date | 1,155.6492 USD (2024/08/14) |
52 Weeks Low | date | 825.2400 USD (2023/09/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2023/10/20 | 17:35 | 766.50 EUR | 0.09 | 18 |
Vienna Stock Exchange | 2024/08/16 | 09:05 | 1,079.00 EUR | 0.00 | 1 |
Tradegate | 2024/08/16 | 09:59 | 1,071.50 EUR | 0.03 | 8 |
Stuttgart | 2024/08/16 | 08:10 | 1,075.50 EUR | 0.00 | 1 |
Nasdaq | 2024/08/15 | 22:00 | 1,175.33 USD | 667.78 | 25,048 |
Munich | 2024/08/16 | 08:08 | 1,075.50 EUR | 0.00 | 1 |
London Stock Exchange | 2024/08/14 | 16:31 | 1,155.6492 USD | 0.55 | 2 |
Hanover | 2024/08/16 | 08:01 | 1,069.50 EUR | 0.00 | 1 |
Hamburg | 2024/08/16 | 08:01 | 1,069.50 EUR | 0.00 | 1 |
Frankfurt | 2024/08/16 | 08:08 | 1,076.00 EUR | 0.00 | 1 |
Euronext Milan MTF Trading After Hours | 2024/06/26 | 18:39 | 1,004.50 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/08/14 | 17:44 | 1,049.00 EUR | 0.01 | 1 |
Duesseldorf | 2024/08/16 | 08:10 | 1,071.00 EUR | 0.00 | 1 |
Berlin | 2024/08/16 | 08:08 | 1,075.50 EUR | 0.00 | 1 |
REGENERON PHARMACEUTICALS INC. |
- - |
777 Old Saw Mill River Road - 10591-6707 Tarrytown |
Telefon: +1-914-847-7000 |
Fax: + |
E-mail: usinfo@regeneron.com |
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
George Yancopoulos | Chairman of Board of Directors |
Bonnie Bassler | Member of Board of Directors |
Craig Thompson | Member of Board of Directors |
David Schenkein | Member of Board of Directors |
Huda Zoghbi | Member of Board of Directors |
Joseph Goldstein | Member of Board of Directors |
Kathryn Guarini | Member of Board of Directors |
Michael Brown | Member of Board of Directors |
N. Coles | Member of Board of Directors |
Arthur Ryan | Member of Board of Directors |
Christine Poon | Member of Board of Directors |
George Sing | Member of Board of Directors |
Leonard S. Schleifer | Chairman of Managing Board |
George D. Yancopoulos | Member of Executive Committee |
Bob McCowan | Member of Executive Committee |
Joseph J. LaRosa | Member of Executive Committee |
Marion McCourt | Member of Executive Committee |
Melissa Lozner | Member of Executive Committee |
Robert E. Landry | Member of Executive Committee |
Sally A. Paull | Member of Executive Committee |
Smita Pillai | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer